Truist Financial Corp and
CWM LLC have offloaded shares of
Takeda Pharmaceutical while
GAMMA Investing LLC and
Raymond James & Associates have stepped in to purchase new stakes. Furthermore, despite the 6.19% and 5.9% drop of Takeda's stock within four-week intervals, many believe a turnaround is close at hand based off the company's underpriced valuation. The stock has also been upgraded to a
Strong Buy according to a rating update. In a deal with
ImmunoGen, Takeda has licensed potentially profitable technology although the company experienced a blow to its profit forecast due to pipeline impairments.
Despite lowering in value, earning a
1-Year Low at $13.08, Takeda's shareholders experienced a
8.8% CAGR over the last 3 years. They are also set to receive a dividend of ¥94.00 soon. However, further competition in the market, indicated by MORF's ulcerative colitis drug, adds another hurdle for Takeda to overcome.
On the brighter side, with the FDA approval of
Eohilia, Takeda's portfolio strengthens, providing a buffer against recent downfalls.
Investors seem divided on Takeda's current value, as some think it is fairly valued or undervalued, while others perceive growth issues. Regardless, many continue to purchase Takeda Pharmaceutical shares because of potential upside.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Wed, 08 May 2024 10:36:00 GMT -
Rating 0
- Innovation 5
- Information 8
- Rumor -3
